Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Regeneron Pharmaceuticals in a note issued to ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Leerink Partners made an adjustment to Regeneron Pharmaceuticals' (NASDAQ:REGN) stock, reducing the price target from $880 to $762 while maintaining a Market Perform rating. The stock, currently ...

Marion McCourt; Executive Vice President - Commercial; Regeneron Pharmaceuticals Inc. Christopher Fenimore; Chief Financial Officer, Senior Vice President - Finance; Regeneron Pha ...

UBS has recently reduced Regeneron Pharmaceuticals Inc (REGN) stock to Neutral rating, as announced on January 16, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...